TuHURA Biosciences, Inc. - Common Stock · Transaction Jul 13, 2025 · Filed Aug 9, 2025 · $50,001 to $100,000
XNAS · HURA
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
TuHURA Biosciences, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
$1.98
Follow $HURA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $HURA by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredThu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET · HURA
MethodologySentiment absence reason unknown
HURA
TuHURA Biosciences, Inc. Common Stock
Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
38/ 100
Veridion Score
Lower range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is HURA moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About TuHURA Biosciences, Inc. Common Stock
PHARMACEUTICAL PREPARATIONSListed since
2024
Employees
22
Country
US
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$1.98
Last session
Day high
$1.98
Last session
Day low
$1.98
Last session
Previous close
$1.98
52W high
$3.15
-37.14% from high
52W low
$0.4400
57% of range
Market cap
$126.2M
EPS
$-0.6200
Beta
1.91
Shares out
63.7M
Avg volume
203.7K
VWAP
$1.98
Last session
Price history computed in-house
1W
-5.71%
1M
-5.26%
3M
-18.85%
1Y
-24.14%
YTD
+161.66%
SMA 50 $2.13 · below
SMA 200 $1.85 · above
52W position 57%
HURA overview
Related filings and maps
Public disclosures
Congress activity in HURA
Official filing ↗
TuHURA Biosciences, Inc. - Common Stock · Transaction Nov 25, 2024 · Filed Jan 7, 2025 · $1,001 to $15,000
TuHURA Biosciences, Inc. - Common Stock · Transaction Oct 18, 2024 · Filed Nov 21, 2024 · $100,001 to $250,000
Federal contracts
HURA contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for HURA in this window.
Lobbying spend
HURA lobbying filings, year to date.
Registered lobbying filings matched to TuHURA Biosciences, Inc. Common Stock.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for HURA in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for HURA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.